naa a22 4500 510763928 CHVBK 20180411083149.0 cr unu---uuuuu 180411e20131001xx s 000 0 eng 10.1007/s12094-013-1001-9 doi (NATIONALLICENCE)springer-10.1007/s12094-013-1001-9 Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences [Elektronische Daten] [Jun Ren, Lijun Di, Guohong Song, Jing Yu, Jun Jia, Yuling Zhu, Ying Yan, Hanfang Jiang, Xu Liang, Li Che, Jie Zhang, Fengling Wan, Xiaoli Wang, Xinna Zhou, Herbert Lyerly] Background: We hypothesized that combination of dendritic cell (DC) with autologous cytokine-induced killer (CIK) immunotherapy in setting of high-dose chemotherapy (HDC) would be effective for selected metastatic breast cancer (MBC) patients. Patients and methods: Our previous work showed thiotepa could eradicate breast cancer stem cells. From 2004 to 2009, 79 patients received standard dose chemotherapy (SDC) of 75mg/m2 docetaxel and 75mg/m2 thiotepa versus 87 patients of HDC+DC/CIK: 120mg/m2 docetaxel to mobilize peripheral CD34+ progenitor cells, a sequence of HDC (120mg/m2 docetaxel, plus 175mg/m2 thiotepa)+DC/CIK, with or without 400mg/m2 carboplatin depending upon bone marrow function. The endpoints were response rates (RR), progression-free survival (PFS), and overall survival (OS). Results: Compared with SDC, PFS and OS were improved in HDC+DC/CIK (median PFS 10.2 vs. 3.7months, P<0.001; median OS 33.1 vs. 15.2months, P<0.001). Patients of pre-menopausal, HDC as first-line treatment after metastasis, or with visceral metastasis showed prolonged PFS and OS. SDC group also achieved the similar response as previous reports. Conclusion: Our study demonstrated the novel combination of HDC with DC/CIK to be an effective choice for the selected MBC population, in which choosing appropriate chemo regimens played important roles, and also specific HDC regimen plus DC/CIK immunotherapy showed the clinical benefits compared with chemotherapy alone. Federación de Sociedades Españolas de Oncología (FESEO), 2013 Metastatic breast cancer nationallicence High-dose chemotherapy nationallicence Immunotherapy nationallicence Dendritic cells nationallicence Cytokine-induced killers nationallicence Ren Jun Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut Di Lijun Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut Song Guohong Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut Yu Jing Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut Jia Jun Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut Zhu Yuling Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut Yan Ying Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut Jiang Hanfang Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut Liang Xu Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut Che Li Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut Zhang Jie Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut Wan Fengling Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut Wang Xiaoli Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut Zhou Xinna Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut Lyerly Herbert Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut Clinical and Translational Oncology Springer Milan 15/10(2013-10-01), 780-788 1699-048X 15:10<780 2013 15 12094 https://doi.org/10.1007/s12094-013-1001-9 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-013-1001-9 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Ren Jun Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut NATIONALLICENCE 700 1- Di Lijun Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut NATIONALLICENCE 700 1- Song Guohong Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut NATIONALLICENCE 700 1- Yu Jing Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut NATIONALLICENCE 700 1- Jia Jun Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut NATIONALLICENCE 700 1- Zhu Yuling Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut NATIONALLICENCE 700 1- Yan Ying Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut NATIONALLICENCE 700 1- Jiang Hanfang Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut NATIONALLICENCE 700 1- Liang Xu Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut NATIONALLICENCE 700 1- Che Li Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut NATIONALLICENCE 700 1- Zhang Jie Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut NATIONALLICENCE 700 1- Wan Fengling Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut NATIONALLICENCE 700 1- Wang Xiaoli Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut NATIONALLICENCE 700 1- Zhou Xinna Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut NATIONALLICENCE 700 1- Lyerly Herbert Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Rd, 100142, Beijing, China aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/10(2013-10-01), 780-788 1699-048X 15:10<780 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer